Ruserontinib
As of the edition of 20 October 2026, Ruserontinib is a small molecule: of no established status; acts on ABL1, EGFR and FLT3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Small molecule
- Registered trials
- 9, 0 stopped early
- Disease areas
- Blood and lymph; Cancer
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 3 | 0 | 0 |
| Phase 2 | 2 | 0 | 1 | 0 |
| Phase 3 | 1 | 0 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Cspc | Lead sponsor of trials | 2016 to now |